Clinical Study Results, Financial Results, Prestigious Awards, and Regulatory Approvals - Research Report on Abbott, Opko, Varian Medical Systems, ICU Medical and Quintiles

NEW YORK, October 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Abbott Laboratories (NYSE: ABT), Opko Health, Inc. (NYSE: OPK), Varian Medical Systems Inc. (NYSE: VAR), ICU Medical, Inc. (NASDAQ: ICUI) and Quintiles Transnational Holdings Inc. (NYSE: Q). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

On October 18, 2013, Abbott Laboratories (Abbott) issued a press release stating that a new study supported by the Company and conducted by leading researchers at the University of Southern California, Stanford University, The Harris School at The University of Chicago and Precision Health Economics, discovered that the use of oral nutritional supplements decreased the probability of 30-day hospital readmission, length of stay and costs among hospitalized Medicare patients aged 65 and over. According to Abbott, the study demonstrated that oral nutritional supplements were associated with a decreased probability of 30-day readmission among Medicare patients aged 65 and over who could be tracked for readmission, with 8.4% reduction for patients with any diagnosis, 10.1% reduction for congestive heart failure patients, and 12.0% reduction for acute myocardial infarction patients. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05c1_ABT]

--

Opko Health, Inc. Research Report

On October 21, 2013, Opko Health, Inc. (OPKO) announced that Pharmadiet, S.L.U. (Pharmadiet), its Barcelona, Spain subsidiary, received final marketing approval from Spain's health authority (Agencia Española de Medicamentos y Productos Sanitarios) for commercialization of its oral and injectable formulations of citicoline. OPKO stated that it expects to start commercialization of its citicoline products in Spain during Q1 2014, and that the products will be significant contributors to Pharmadiet's sales and earnings. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

--

Varian Medical Systems Inc. Research Report

On October 21, 2013, Varian Medical Systems Inc. (Varian) announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for RapidPlan, a radiotherapy treatment planning tool designed to enhance quality, consistency, and efficiency in radiotherapy treatment planning. The Company stated that RapidPlan allows enhanced treatment planning by providing clinics with knowledge-based models that generate high-quality personalized treatment plans for their patients. Vice President of Product Management at Varian, Corey Zankowski said, "RapidPlan streamlines the planning process by enabling users to tap into knowledge derived from historical treatment plans. It considers the unique characteristics of the current patient and helps to generate a new treatment plan that approaches the optimal in terms of achieving the radiation oncologist's tumor coverage and normal tissue sparing goals." Varian informed that RapidPlan received FDA clearance for distribution in US and is currently not available in other parts of the world. The Full Research Report on Varian Medical Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bd48_VAR]

--

ICU Medical, Inc. Research Report

On October 21, 2013, ICU Medical, Inc. (ICU Medical) announced its Q3 2013 financial results. The Company reported that its total revenue increased 1.7% YoY to $82.8 million. Net income stood at $11.0 million or $0.72 per diluted share compared to $12.2 million or $0.82 per diluted share in Q3 2012. Commenting on the results, Scott Lamb, ICU Medical's CFO, stated, "Our third quarter revenue was driven by strong performance of oncology products and robust improvements in critical care on a sequential basis, which were offset by decreases in infusion therapy and other product categories. International sales were up 19.0%, while domestic sales decreased 3.5% year over year." For the full- year FY 2013, the Company revised its guidance and expects revenue to be in the range of $319 million to $321 million and diluted EPS to be within $2.50 and $2.55 range. ICU Medical also announced that the Company's President and CEO, Dr. George Lopez, has stepped down from his position due to health concerns, and the Board of Directors has appointed Steven Riggs, who is the current Vice President of Operations as Acting CEO, with immediate effect. The Company informed that Dr. Lopez will continue as the Chairman of the Board of Directors and will remain an employee of the Company in a new position in the Company's Research and Development Department. The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/be3b_ICUI]

--

Quintiles Transnational Holdings Inc. Research Report

On October 14, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that it has been awarded the Society for Clinical Research Sites' (SCRS) 2013 Clinical Research Organization (CRO) Eagle Award- which recognizes outstanding leadership, professionalism, integrity, passion and dedication and is voted on by the sites themselves. Senior Vice President, Integrated Site Services of Quintiles, Lindy Jones stated, "We are thrilled to receive the Eagle Award which recognizes that we understand and are dedicated to working closely with all of our investigative sites. We are especially pleased because we were chosen by the sites themselves." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9f5c_Q]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner